Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy
New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristic...
- Autores:
-
Cañas Dávila, Carlos Alberto
Tobón, Gabriel Jaime
Vélez, Juan Diego
Pineda, Juan Carlos
Betancurt, J. F.
Bonilla Abadía, Fabio
- Tipo de recurso:
- Article of investigation
- Fecha de publicación:
- 2014
- Institución:
- Universidad ICESI
- Repositorio:
- Repositorio ICESI
- Idioma:
- eng
- OAI Identifier:
- oai:repository.icesi.edu.co:10906/81239
- Acceso en línea:
- http://www.ncbi.nlm.nih.gov/pubmed/24402739
http://hdl.handle.net/10906/81239
http://dx.doi.org/10.1007/s10067-013-2475-0
- Palabra clave:
- Ciencias socio biomédicas
Pneumocystis jiroveci
Medical sciences
Lupus eritematoso sistémico
- Rights
- openAccess
- License
- https://creativecommons.org/licenses/by-nc-nd/4.0/
| Summary: | New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristics of the disease, the mechanisms of rituximab action, environmental factors, and the biological characteristics of the fungus. We report two patients with SLE who developed PJP after rituximab therapy. |
|---|